Recent results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) provided evidence that targeting IL-1β with canakinumab significantly reduced major cardiovascular event rates, including HF hospitalizations (48), and that the magnitude of risk reduction was correlated with the magnitude of IL-6 reduction (44). Here, IL1B is linked to hydrops fetalis.